鞘内注射onasemnogene abeparvovec治疗初治脊髓性肌萎缩症:一项3期随机对照试验
STEER试验为52周、3期、多中心、随机、假手术对照、双盲研究,评估一次性鞘内注射onasemnogene abeparvovec(OAV101 IT)在2岁至<18岁、初治、能坐但从未独立行走的脊髓性肌萎缩症(SMA)患者中的疗效与安全性。共126例接受OAV101 IT(n=75)或假手术(n=51),主要终点达标:OAV101 IT组HFMSE评分较假手术组显著升高,最小二乘均值差1.88(95%CI 0.51-3.25;P=0.0074)。两组不良事件、严重不良事件及特殊关注不良事件总体发生率相似。
要点
- OAV101 IT组HFMSE评分较假手术组显著升高,最小二乘均值差1.88(95%CI 0.51-3.25;P=0.0074)。
- 两组不良事件、严重不良事件及特殊关注不良事件总体发生率相似。
- OAV101 IT组2例、假手术组1例出现感觉症状。
核心结论
- 一次性OAV101 IT较假手术对照在运动功能方面表现出统计学显著改善。
- 总体安全性发现可接受,OAV101 IT组与假手术组不良事件、严重不良事件及特殊关注不良事件发生率相似。
研究设计与样本
- STEER(NCT05089656)为52周、3期、多中心、随机、假手术对照、双盲试验,评估一次性鞘内注射onasemnogene abeparvovec(OAV101 IT)治疗脊髓性肌萎缩症(SMA)。
- 纳入患者年龄2岁至<18岁,初治,能坐但从未独立行走。
- 共126例患者接受OAV101 IT(n=75)或假手术(n=51)。
- 主要疗效终点为Hammersmith功能运动量表扩展版(HFMSE)评分较基线的变化。
主要发现
- 主要终点达标:OAV101 IT组HFMSE评分较假手术组显著升高,最小二乘均值差1.88(95%CI 0.51-3.25;P=0.0074)。
- 不良事件、严重不良事件及特殊关注不良事件总体发生率两组相似。
- 转氨酶升高不常见,多为低级别且一过性。
- OAV101 IT组2例、假手术组1例出现感觉症状。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STEER ( NCT05089656 ) was a 52-week, phase 3, multicenter, randomized, sham-controlled, double-blind trial evaluating intrathecal onasemnogene abeparvovec (OAV101 IT), a one-time gene transfer therapy, in patients with spinal muscular atrophy (SMA). Participants ranged in age from 2 years to <18 years, were treatment-naive and were able to sit but never walked independently. Primary efficacy endpoint was change from baseline in Hammersmith Functional Motor Scale-Expanded (HFMSE) score. In total, 126 patients received OAV101 IT (n = 75) or a sham procedure (n = 51). The primary endpoint was met: patients treated with OAV101 IT demonstrated a significant increase in HFMSE score compared with sham (least squares mean difference, 1.88 (95% confidence interval: 0.51-3.25); P = 0.0074). Overall incidence of adverse events (AEs), serious adverse events (SAEs) and adverse events of special interest (AESI) was similar between groups. Transaminase increases were infrequent; most were low grade and transient. Two participants in the OAV101 IT arm and one participant in the sham arm developed sensory symptoms. One-time OAV101 IT demonstrated a statistically significant improvement in motor function compared with sham control. The overall safety findings were acceptable, with similar incidences of AEs, SAEs and AESI in the OAV101 IT and sham groups. Trial registration: ClinicalTrials.gov identifier: NCT05089656 .
引用
- Proud CM, Vũ DC, Wilmshurst JM, et al. Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial. Nat Med. 2025. PMID: 41360993. doi:10.1038/s41591-025-04103-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。